Revised Drug Eluting Stent Addresses Wider Range of Lesions

A bioabsorbable polymer hybrid Drug Eluting Stent (DES) now offers one of the longest ranges on the market, across all diameters.

The BIOTRONIK (Berlin, Germany) Orsiro Hybrid DES is intended for the treatment of coronary artery stenosis with a hybrid combination of passive and active components. PROBIO passive coating encapsulates the stent, minimizing interaction between the metal stent and the surrounding tissue. The active coating, BIOlute, contains a highly biocompatible polymer that delivers a limus drug via a bio-absorbable matrix. This hybrid coating is layered on top of the high performance PRO-Kinetic Energy stent platform, a cobalt-chromium alloy, which allows for thinner struts, while maintaining optimal radial strength and radiopacity.


The thin struts, only 60 µm in diameter, also result in exceptional flexibility and deliverability of the stent when using proprietary Pantera balloon technology with an enhanced force transmission shaft (EFT), which adds pushability and trackability. The efficacy and safety of the Orsiro line was recently demonstrated in the BIOFLOW-II study, presented at the 2013 EuroPCR congress, which evaluated the safety and efficacy of Orsiro compared to the Abbott XIENCE PRIME. The study found no significant differences for the clinical end-points at nine months, and no stent thrombosis in either arm.

“With the addition of the 35 and 40 mm lengths, Orsiro now has a complete size range. The new lengths, in combination with the great deliverability, means that physicians can use Orsiro across a wider range of lesions,” said Alain Aimonetti, vice president of sales and business development at BIOTRONIK.

DESs are stents placed into narrowed, diseased coronary arteries that slowly release a drug to block cell proliferation. This prevents fibrosis that, together with blood clots, could otherwise block the stented artery, a process called restenosis. DESs have been shown to be statistically superior to bare-metal stents (BMS) for the treatment of native coronary artery narrowing, having lower rates of major adverse cardiac events (MACE).

Related Links:
BIOTRONIK